CO2020001801A2 - Tratamiento de afecciones óseas anormales en pacientes con deficiencia de esfingomielinasa ácida - Google Patents
Tratamiento de afecciones óseas anormales en pacientes con deficiencia de esfingomielinasa ácidaInfo
- Publication number
- CO2020001801A2 CO2020001801A2 CONC2020/0001801A CO2020001801A CO2020001801A2 CO 2020001801 A2 CO2020001801 A2 CO 2020001801A2 CO 2020001801 A CO2020001801 A CO 2020001801A CO 2020001801 A2 CO2020001801 A2 CO 2020001801A2
- Authority
- CO
- Colombia
- Prior art keywords
- patients
- acid sphingomyelinase
- treatment
- abnormal bone
- sphingomyelinase deficiency
- Prior art date
Links
- 208000034012 Acid sphingomyelinase deficiency Diseases 0.000 title abstract 3
- 230000002159 abnormal effect Effects 0.000 title abstract 2
- 210000000988 bone and bone Anatomy 0.000 title abstract 2
- 101000785978 Homo sapiens Sphingomyelin phosphodiesterase Proteins 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 102000048866 human SMPD1 Human genes 0.000 abstract 1
- 108010092496 olipudase alfa Proteins 0.000 abstract 1
- 229950010922 olipudase alfa Drugs 0.000 abstract 1
- 231100001055 skeletal defect Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762549732P | 2017-08-24 | 2017-08-24 | |
| EP17306720 | 2017-12-07 | ||
| PCT/IB2018/056346 WO2019038685A2 (en) | 2017-08-24 | 2018-08-22 | TREATMENT OF ABNORMAL BONE CONDITIONS IN PATIENTS WITH ACIDIC SPHINGOMYELASE DISEASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2020001801A2 true CO2020001801A2 (es) | 2020-04-01 |
Family
ID=63556374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2020/0001801A CO2020001801A2 (es) | 2017-08-24 | 2020-02-18 | Tratamiento de afecciones óseas anormales en pacientes con deficiencia de esfingomielinasa ácida |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11898175B2 (enExample) |
| EP (1) | EP3672622B1 (enExample) |
| JP (3) | JP7216075B2 (enExample) |
| KR (2) | KR20250025051A (enExample) |
| CN (2) | CN118453843A (enExample) |
| AU (2) | AU2018319565B2 (enExample) |
| BR (1) | BR112020003541A2 (enExample) |
| CA (1) | CA3073648A1 (enExample) |
| CO (1) | CO2020001801A2 (enExample) |
| ES (1) | ES2970423T3 (enExample) |
| IL (1) | IL272757B2 (enExample) |
| MX (2) | MX2020002106A (enExample) |
| NZ (1) | NZ762860A (enExample) |
| PL (1) | PL3672622T3 (enExample) |
| SG (1) | SG11202001544VA (enExample) |
| TW (1) | TWI791040B (enExample) |
| WO (1) | WO2019038685A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102094253B1 (ko) * | 2009-08-28 | 2020-03-31 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법 |
| UY38238A (es) * | 2018-05-25 | 2019-12-31 | Genzyme Corp | Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida |
| JP7568648B2 (ja) * | 2019-05-31 | 2024-10-16 | ジェンザイム・コーポレーション | 二次元ｌｃ－ｍｓ／ｍｓシステム |
| CN112773779B (zh) * | 2021-02-04 | 2022-08-16 | 上海交通大学医学院附属新华医院 | 氨溴索、千金藤和汉防已在治疗酸性鞘磷脂酶缺乏症中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5773278A (en) | 1991-05-03 | 1998-06-30 | Mount Sinai Medical Center | Acid sphingomyelinase gene |
| CN1302897A (zh) | 1999-10-28 | 2001-07-11 | 上海博容基因开发有限公司 | 一种新的多肽——人酸性鞘磷酯酶相似的磷酸二酯酶21和编码这种多肽的多核苷酸 |
| WO2006130769A2 (en) * | 2005-06-02 | 2006-12-07 | Tercica, Inc. | Methods for treatment of growth disorders |
| KR102094253B1 (ko) * | 2009-08-28 | 2020-03-31 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 산성 스핑고미엘리나제 결핍을 치료하기 위한 투여량 단계적 증가 효소 대체 요법 |
| HK1207005A1 (en) | 2012-03-02 | 2016-01-22 | 夏尔人类遗传性治疗公司 | Compositions and methods for treating type iii gaucher disease |
| WO2014093354A1 (en) | 2012-12-12 | 2014-06-19 | Teva Pharmaceutical Industries Ltd. | Fusion of human growth hormone and albumin, formulation and uses thereof |
| PL3004896T3 (pl) | 2013-06-07 | 2020-04-30 | Genzyme Corporation | Marker zaburzeń kwaśnej spfingomielinazy i jego zastosowania |
-
2018
- 2018-08-22 SG SG11202001544VA patent/SG11202001544VA/en unknown
- 2018-08-22 MX MX2020002106A patent/MX2020002106A/es unknown
- 2018-08-22 KR KR1020257004704A patent/KR20250025051A/ko active Pending
- 2018-08-22 PL PL18768948.4T patent/PL3672622T3/pl unknown
- 2018-08-22 BR BR112020003541-6A patent/BR112020003541A2/pt unknown
- 2018-08-22 CA CA3073648A patent/CA3073648A1/en active Pending
- 2018-08-22 ES ES18768948T patent/ES2970423T3/es active Active
- 2018-08-22 CN CN202410508209.2A patent/CN118453843A/zh active Pending
- 2018-08-22 AU AU2018319565A patent/AU2018319565B2/en active Active
- 2018-08-22 EP EP18768948.4A patent/EP3672622B1/en active Active
- 2018-08-22 TW TW107129257A patent/TWI791040B/zh active
- 2018-08-22 NZ NZ762860A patent/NZ762860A/en unknown
- 2018-08-22 WO PCT/IB2018/056346 patent/WO2019038685A2/en not_active Ceased
- 2018-08-22 JP JP2020511325A patent/JP7216075B2/ja active Active
- 2018-08-22 US US16/641,116 patent/US11898175B2/en active Active
- 2018-08-22 KR KR1020207008213A patent/KR102769578B1/ko active Active
- 2018-08-22 CN CN201880067498.XA patent/CN111344003B/zh active Active
- 2018-08-22 IL IL272757A patent/IL272757B2/en unknown
-
2020
- 2020-02-18 CO CONC2020/0001801A patent/CO2020001801A2/es unknown
- 2020-02-24 MX MX2023010908A patent/MX2023010908A/es unknown
-
2023
- 2023-01-18 JP JP2023005602A patent/JP7431356B2/ja active Active
-
2024
- 2024-01-10 US US18/409,535 patent/US20240218338A1/en active Pending
- 2024-01-31 JP JP2024012534A patent/JP2024050732A/ja active Pending
-
2025
- 2025-05-12 AU AU2025203384A patent/AU2025203384A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020001801A2 (es) | Tratamiento de afecciones óseas anormales en pacientes con deficiencia de esfingomielinasa ácida | |
| DOP2017000271A (es) | Métodos de acondicionamiento de pacientes para tratamiento con linfocitos t | |
| BR112019007210A2 (pt) | métodos e composições para o tratamento da doença de fabry | |
| UY34593A (es) | Miméticos sintéticos de apelina para el tratamiento de falla cardiaca | |
| DOP2017000097A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
| DOP2017000272A (es) | Métodos de diagnóstico para tratamiento con linfocitos t | |
| BR112017026709A2 (pt) | tratamento e diagnóstico de câncer | |
| SV2017005416A (es) | Alfa-glucosidasa ácida muy potente con hidratos de carbono potenciados | |
| MX359201B (es) | Polipeptidos que se unen al complemento humano 5 (c5). | |
| MX2018002546A (es) | Composiciones que comprenden un compuesto de urolitina. | |
| ZA202503350B (en) | Semaglutide in medical therapy | |
| BR112017014361A2 (pt) | métodos para aperfeiçoamento de terapia celular | |
| BR112015013349A2 (pt) | trieptanoína para o tratamento de deficiência de transportador de glicose 1 | |
| BR112019017393A2 (pt) | formulações de evolocumab de baixa viscosidade, alta concentração e métodos para produzir as mesmas | |
| MY185691A (en) | An asseointegrable device | |
| BR112018003238A2 (pt) | seleção de pacientes para terapia de combinação | |
| CL2016001578A1 (es) | Piperidiniltetrahidroquinolinas sustituidas y su uso como antagonistas de los adenoreceptores alpha-2c. | |
| MX370570B (es) | Marcador para trastornos de la esfingomielinasa acida y sus usos. | |
| MX2016012248A (es) | Composiciones para el tratamiento de autodigestion. | |
| CL2017003323A1 (es) | Composición para el tratamiento de nafld | |
| BR112021020499A2 (pt) | Monitoramento de terapia de gene | |
| MY197247A (en) | Recombinant glycoproteins and uses thereof | |
| CL2019002155A1 (es) | Proteínas de fusión del factor ix y procedimientos de preparación y utilización de las mismas. | |
| GB2530224A (en) | Enhancement of osteogenic potential of bone grafts | |
| BR112017001372A2 (pt) | dispositivo médico com visibilidade melhorada para inserção em um corpo humano ou animal e/ou para o contato com tecido humano ou animal, e método de revestimento de um dispositivo médico |